PLK1 and nasopharyngeal carcinoma: Indeed, pharmacological inhibition of PLK1 and AURKA demonstrated superior antitumor activity compared with either single drug treatment in nasopharyngeal carcinoma and was minimally harmful to normal epithelial cells.